undamentalytics Newsletter
Sign in

Arcadia Biosciences, Inc. balance sheet

At the end of fiscal 2025, Arcadia Biosciences, Inc. had total assets of $6.5m, total liabilities of $2.4m and shareholders' equity of $4.1m. It held $259,000 in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents1724291281429217404
Receivables1101011111101
Inventory0000024421111
Total current assets19525215232832352515966
Goodwill——————0——————
Total assets257457172433474429201476
Deferred revenue (current)1111000——————
Total current liabilities11334366544322
Short-term debt100——010—————
Long-term debt9252500020—————
Total debt1425250003000000
Total liabilities27343491124191387725
Shareholders' equity−854022813828312113641
Non-controlling interests and other (assets − liabilities − equity)83————————————
Shares outstanding——111m————1m1m1m1m1m2m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CBUS vs RKDAPFAI vs RKDARKDA vs WFCF

More: Agricultural Products & Services stocks compared, Consumer Staples sector, rankings of US companies

Figures from Arcadia Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcadia Biosciences, Inc.